From Financial Modeling Prep: 2025-05-07 13:06:00

The Chief Human Resources Officer of Organon & Co. (NYSE:OGN) purchased 5,500 shares, increasing total ownership to 62,974 shares. OGN is being investigated for potential violations of federal securities laws after a 7% revenue decline to $1.51 billion. The stock price of OGN currently stands at $8.93, reflecting a 2.19% decrease.

Organon & Co. (NYSE:OGN) is a pharmaceutical company specializing in women’s health, biosimilars, and established brands. Despite an insider purchase, the company is under investigation by multiple law firms for potential securities law violations. OGN’s Q1 FY25 revenue declined by 7% to $1.51 billion, missing market expectations and sparking investor concerns.

Bronstein, Gewirtz & Grossman, LLC, along with other law firms, are investigating Organon for potential securities law violations. Investors who suffered losses are urged to participate in the investigation. OGN’s stock is currently priced at $8.93, reflecting a 2.19% decrease with significant fluctuations throughout the day.

Robbins Geller Rudman & Dowd LLP has joined the investigation into Organon & Co. (NYSE:OGN) for potential securities law violations. The focus is on false or misleading statements by Organon and its executives. OGN’s stock price is currently at $8.93, with a market capitalization of approximately $2.32 billion and a trading volume of 4,289,304 shares on the NYSE.



Read more at Financial Modeling Prep:: Organon & Co. Faces Legal Scrutiny Amid Inside…